aBLA Filing Intelligence & Biosimilar Opportunity

Imdelltra

Tarlatamab-Dlle

Anticancer

Intravenous Infusion

Imdelltra is used to treat adults with extensive-stage small cell lung cancer (ES-SCLC) that has returned after platinum-based chemotherapy.

Approval Date

16-May-24

Data Exclusivity Expiry

16-May-28

Market Exclusivity Expiry

16-May-36

Commercial snapshot

Market performance & projections

Revenue ($M)

637

CAGR (%)

39.18%

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1,260

2027

1,666

2028

2,127

2029

2,390

2030

2,734

2031

3,050

2032

3,306

Molecule profile

Details & specifications

Molecule

Tarlatamab-Dlle

Innovator

AMGEN

Dosage Form

Intravenous Infusion

Strength

1 mg/vial and 10 mg/vial

Therapeutic Category

Anticancer

Usage

To treat extensive stage small cell lung cancer

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets